ArticlePloS one2011
Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- HIF-1 attenuates high-fiber diet-mediated proliferation and stemness of colonic epithelium.Gut microbes · 2025Article
- In vivo optical imaging of tumor stromal cells with hypoxia-inducible factor activity.Cancer science · 2023Article
- Genetically Encoded Tools for Research of Cell Signaling and Metabolism under Brain Hypoxia.Antioxidants (Basel, Switzerland) · 2020Review
- Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- How Non-invasiveFrontiers in physiology · 2020Review
- Transgenic Animal Models to Visualize Cancer-Related Cellular Processes by Bioluminescence Imaging.Frontiers in pharmacology · 2019Review
- Imaging to study solid tumour origin and progression: lessons from research and clinical oncology.Immunology and cell biology · 2017Review
- Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- Sustained Effect of Hyaluronic Acid in Subcutaneous Administration to the Cochlear Spiral Ganglion.PloS one · 2016Article
- Article
- Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.PloS one · 2015Article
- Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.British journal of cancer · 2014Article
- In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies.Cellular and molecular life sciences : CMLS · 2014Review
- Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.Free radical biology & medicine · 2013Review
- In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.Journal of neuroscience research · 2013Article
- Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma.Virology journal · 2013Article
- Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.Cancer discovery · 2013Review
- Luminescence-based in vivo monitoring of NF-κB activity through a gene delivery approach.Cell communication and signaling : CCS · 2013Article
- Article
- Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn humans, imaging of tumors provides rapid, accurate assessment of tumor growth and location. In laboratory animals, however, the imaging of spontaneously occurring tumors continues to pose many technical and logistical problems. Recently a mouse model was generated in which a chimeric protein consisting of HIF-1α oxygen-dependent degradation domain (ODD) fused to luciferase was ubiquitously expressed in all tissues. Hypoxic stress leads to the accumulation of ODD-luciferase in the tissues of this mouse model which can be identified by non-invasive bioluminescence measurement. Since solid tumors often contain hypoxic regions, we performed proof-of-principle experiments testing whether this transgenic mouse model may be used as a universal platform for non-invasive imaging analysis of spontaneous solid tumors. METHODS AND MATERIALS: ODD-luciferase transgenic mice were bred with MMTV-neu/beclin1+/- mice. Upon injection of luciferin, bioluminescent background of normal tissues in the transgenic mice and bioluminescent signals from spontaneously mammary carcinomas were measured non-invasively with an IVIS Spectrum imaging station. Tumor volumes were measured manually and the histology of tumor tissues was analyzed.
conclusionOur results show that spontaneous mammary tumors in ODD-luciferase transgenic mice generate substantial bioluminescent signals, which are clearly discernable from background tissue luminescence. Moreover, we demonstrate a strong quantitative correlation between the bioluminescent tumor contour and the volume of palpable tumors. We further demonstrate that shrinkage of the volume of spontaneous tumors in response to chemotherapeutic treatment can be determined quantitatively using this system. Finally, we show that the growth and development of spontaneous tumors can be monitored longitudinally over several weeks. Thus, our results suggest that this model could potentially provide a practical, reliable, and cost-effective non-invasive quantitative method for imaging spontaneous solid tumors in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.